The uses of embryonic stem cells to repair or replace body organs was discussed earlier.
(2 Feb, 2008, 1305 hrs IST, TNN)* Writankar Mukherjee predicts in The The Economic Times that
"The day may not be too far when India may become a global hub for cure to deadly diseases such as diabetes, cancer, neurology and cardiac problems."
Estimates suggest about 15-20 million people will go for stem cell therapies every year in India.
Reliance Group, Apollo Hospitals, Fortis, LifeCell and Cryobanks, Manipal Group are investing millions in developing stem cell therapy.
Manipal Group** has invested close to Rs 50 crore
Cryobanks plans to invest some Rs 500 crore to develop five therapy centres with the first one coming up in Naresh Trehan's 'MediCity' project in Gurgaon.
Cryobanks plans to invest some Rs 500 crore.
"These centres will offer therapy to treat 75 diseases such as blood disorders, thalassemia, leukaemia, certain metabolic disorders and cancer with a 90% success rate," says CEO C. V. Nerikar of Cryobanks.
Cryobank plans to develop five therapy centres with the first one coming up in Naresh Trehan's 'MediCity' project in Gurgaon.
"While we will start with stem cell transplantation, concurrent pilot stage trials will go on for other therapies,” adds Cryobanks CEO, C. V. Nerikar.
"India has the opportunity to be a global force in biotech and stem cell research can be an important constituent of this aspect," president and CEO K. V. Subramaniam of Reliance Life Science (RLS) is quoted to have said in this report.
And here is the rest of it.
Will the companies succeed in harvesting money from the benefits of treatment using stem cell research will be expected to be seen in the near future.
*
2 Feb, 2008, 1305 hrs IST,Writankar Mukherjee, TNN
Economic Times, India
** Manipal Group project’s chief scientific officer Satish Totey said.
(2 Feb, 2008, 1305 hrs IST, TNN)* Writankar Mukherjee predicts in The The Economic Times that
"The day may not be too far when India may become a global hub for cure to deadly diseases such as diabetes, cancer, neurology and cardiac problems."
Estimates suggest about 15-20 million people will go for stem cell therapies every year in India.
Reliance Group, Apollo Hospitals, Fortis, LifeCell and Cryobanks, Manipal Group are investing millions in developing stem cell therapy.
Manipal Group** has invested close to Rs 50 crore
Cryobanks plans to invest some Rs 500 crore to develop five therapy centres with the first one coming up in Naresh Trehan's 'MediCity' project in Gurgaon.
Cryobanks plans to invest some Rs 500 crore.
"These centres will offer therapy to treat 75 diseases such as blood disorders, thalassemia, leukaemia, certain metabolic disorders and cancer with a 90% success rate," says CEO C. V. Nerikar of Cryobanks.
Cryobank plans to develop five therapy centres with the first one coming up in Naresh Trehan's 'MediCity' project in Gurgaon.
"While we will start with stem cell transplantation, concurrent pilot stage trials will go on for other therapies,” adds Cryobanks CEO, C. V. Nerikar.
"India has the opportunity to be a global force in biotech and stem cell research can be an important constituent of this aspect," president and CEO K. V. Subramaniam of Reliance Life Science (RLS) is quoted to have said in this report.
And here is the rest of it.
Will the companies succeed in harvesting money from the benefits of treatment using stem cell research will be expected to be seen in the near future.
*
2 Feb, 2008, 1305 hrs IST,Writankar Mukherjee, TNN
Economic Times, India
** Manipal Group project’s chief scientific officer Satish Totey said.
Comments